Respiratory Disease Testing Market Report 2025-2030: AI, Molecular Testing, And Imaging Innovations Drive 5.95% CAGR

(MENAFN- GlobeNewsWire - Nasdaq) F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, and QIAGEN Group Lead

Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The Respiratory Disease Testing Market grew from USD 6.49 billion in 2024 to USD 6.86 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 9.18 billion by 2030.
Over the past few years, transformative shifts have redefined the respiratory disease testing landscape, challenging conventional paradigms while establishing new standards of care. Breakthroughs in diagnostic imaging and molecular technologies, coupled with the increasing integration of artificial intelligence and machine learning, have reoriented traditional testing practices. Innovative imaging techniques such as computed tomography and advanced digital radiography have improved the accuracy of pulmonary assessments, while novel immunoassays and molecular diagnostic tools are offering earlier and more precise detection capabilities.
These technological strides are complemented by a global drive towards personalized medicine, where diagnostics are tailored according to individual patient profiles. As regulatory bodies update standards to keep pace with scientific advancements, there has also been a surge in investments in research and development by both public and private sectors. The confluence of these factors has accelerated market growth, making the industry more agile and responsive to emerging respiratory health challenges. Additionally, a renewed focus on reducing diagnosis turnaround times and enhancing data transparency further bolsters the transition towards a more efficient and patient-focused testing framework.
Regional Trends Shaping the Market
Regional insights elucidate the nuances of market behavior across key geographies. In the Americas, technological innovations are coupled with strong regulatory frameworks and significant investments in public health infrastructure, driving robust market growth. Similarly, the Europe, Middle East & Africa region is characterized by a blend of established health systems and emerging markets where government initiatives and private sector partnerships are catalyzing rapid adoption of advanced testing methodologies. The interplay of socio-economic factors and healthcare investments here creates a fertile ground for sustainable growth and innovation.
In the Asia-Pacific region, increasing healthcare awareness coupled with rising incidences of respiratory ailments has spurred substantial market activity. Economic expansion and urbanization, along with improvements in healthcare infrastructure, are propelling demand for state-of-the-art respiratory disease testing. The balance between cost-effective solutions and technological sophistication remains a guiding factor in market adoption across these regions. These regional insights offer a comprehensive overview of the diverse factors influencing market dynamics and underscore the importance of strategic regional investments and policy adaptations.
Competitive Landscape and Company Insights
The competitive landscape within the respiratory disease testing market is defined by a blend of global conglomerates and innovative startups, each contributing unique technological competencies to the evolving sector. Industry leaders such as Abbott Laboratories, AstraZeneca PLC, and Becton, Dickinson and Company have long been recognized for their contributions to healthcare innovation. In parallel, Bio-Rad Laboratories, Inc., Biomerieux PLC, and Charles River Laboratories continue to push the boundaries of diagnostic excellence. Additionally, companies like COSMED srl, Eurofins Viracor, LLC, and F. Hoffmann-La Roche Ltd. have cemented their positions through sustained investments in advanced diagnostic technologies.
Further reinforcing the competitive environment, prominent players such as Fujifilm Holdings, GE Healthcare, and Koninklijke Philips N.V have been pivotal in integrating cutting-edge imaging solutions with diagnostic testing. The market also sees significant contributions from Medtronic PLC, MGC Diagnostics Corporation by Caire Inc., QIAGEN Group, ResMed, and SDI Diagnostics, Inc., whose strategies increasingly focus on precision diagnostics and data integration. Meanwhile, organizations including Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific maintain strong global footprints through innovative product offerings and strategic market positioning. This diverse yet consolidated competitive landscape is a testament to the market's rapid evolution and its capacity for continual innovation.
The report delves into recent significant developments in the Respiratory Disease Testing Market, highlighting leading vendors and their innovative profiles. These include:

• Abbott Laboratories
• AstraZeneca PLC
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biomerieux PLC
• Charles River Laboratories
• COSMED srl
• Eurofins Viracor, LLC
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings
• GE Healthcare
• Koninklijke Philips N.V.
• Medtronic PLC
• MGC Diagnostics Corporation by Caire Inc.
• QIAGEN Group
• ResMed
• SDI Diagnostics, Inc.
• Seegene Inc.
• Seimens Healthineers AG
• Thermo Fisher Scientific

Actionable Strategies for Industry Leaders
For industry leaders aiming to navigate the complex landscape of respiratory disease testing, several strategic imperatives emerge. Embracing technological advancements is crucial; organizations should invest in scalable diagnostic platforms that integrate modern imaging solutions, molecular diagnostics, and real-time data analytics. It is essential to foster partnerships with academic institutions, industry experts, and technology providers to co-develop next-generation diagnostic tools that can address both current and emerging respiratory challenges.
Organizations must also prioritize agility by aligning their operational strategies with evolving regulatory standards and patient-centric care models. Leveraging data-driven insights can streamline product development processes, optimize supply chains, and enhance customer engagement efforts. Focused investments in research and innovation, alongside a commitment to training and retaining skilled professionals, will ensure that companies remain competitive. Moreover, diversification of product portfolios to include comprehensive testing solutions that cater to varied segments - from test types and technological approaches to age-specific and disease-specific needs - is paramount. These strategic actions will not only enhance market presence but also contribute significantly to improved patient outcomes and operational efficiencies across the sector.
Key Attributes

Report Attribute	Details
No. of Pages	197
Forecast Period	2025 - 2030
Estimated Market Value (USD) in 2025	$6.86 Billion
Forecasted Market Value (USD) by 2030	$9.18 Billion
Compound Annual Growth Rate	5.9%
Regions Covered	Global

Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expanding awareness and increasing prevalence of respiratory illnesses necessitate advanced testing
5.1.1.2. Government initiatives and funding are bolstering research and development of respiratory diagnostics
5.1.1.3. Rise in pollution levels worldwide contributing to increased respiratory ailments and testing demand
5.1.2. Restraints
5.1.2.1. High costs associated with the development and implementation of new diagnostic technologies
5.1.3. Opportunities
5.1.3.1. Integration of artificial intelligence and data analytics in improving diagnostic test accuracy and speed
5.1.3.2. Surge in demand for personalized healthcare solutions stimulates advancements in respiratory testing
5.1.4. Challenges
5.1.4.1. Regulatory and compliance challenges associated with respiratory disease testing solutions
5.2. Market Segmentation Analysis
5.2.1. Component: Rising prevalence of respiratory ailments accelerates the need for reagents & kits
5.2.2. End Users: Growing importance of diagnostic laboratories as they facilitate high-throughput and detailed analysis
5.3. Porter's Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Respiratory Disease Testing Market, by Test Type
6.1. Introduction
6.2. Blood Tests
6.3. Imaging Tests
6.3.1. Chest X-Ray
6.3.2. Computed Tomography
6.4. Pulmonary Function Tests
7. Respiratory Disease Testing Market, by Component
7.1. Introduction
7.2. Instruments
7.3. Reagents & Kits
7.4. Software
8. Respiratory Disease Testing Market, by Age Group
8.1. Introduction
8.2. Adults
8.3. Geriatrics
8.4. Pediatrics
9. Respiratory Disease Testing Market, by Technology
9.1. Introduction
9.2. Imaging Technologies
9.3. Immunoassays
9.4. Microbiology
9.5. Molecular Diagnostics
10. Respiratory Disease Testing Market, by Test Purpose
10.1. Introduction
10.2. Diagnosis
10.3. Monitoring
10.4. Prognosis
10.5. Screening
11. Respiratory Disease Testing Market, by Diseases Type
11.1. Introduction
11.2. Asthma
11.3. Chronic Obstructive Pulmonary Disease (COPD)
11.3.1. Chronic Bronchitis
11.3.2. Emphysema
11.4. Infectious Respiratory Diseases
11.4.1. Influenza
11.4.2. Pneumonia
11.4.3. Tuberculosis
11.5. Lung Cancer
12. Respiratory Disease Testing Market, by End Users
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Home Care Settings
12.4. Hospitals & Clinics
12.5. Research Laboratories
13. Americas Respiratory Disease Testing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Respiratory Disease Testing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Respiratory Disease Testing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Roche enhances respiratory disease diagnostics with advanced multi-virus detection test technology
16.3.2. NIH-backed study has developed an experimental blood test to predict severe respiratory diseases
16.3.3. New national centre launched to improve tests and treatments for respiratory diseases
16.4. Strategy Analysis & Recommendations
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08042025004107003653ID1109402285